Current progress in pharmacogenetics

被引:12
作者
Blakey, John D. [1 ]
Hall, Ian P. [2 ]
机构
[1] Resp Biomed Res Unit, Nottingham NG5 1PB, England
[2] Queens Med Ctr, Div Therapeut & Mol Med, Nottingham NG7 2UH, England
基金
英国惠康基金;
关键词
adverse drug effects; genome-wide association; pharmacogenetics; GENOME-WIDE ASSOCIATION; POLYMORPHISMS; GENOTYPE; DETERMINANT; EDUCATION; THERAPY; ASTHMA; IMPACT;
D O I
10.1111/j.1365-2125.2011.03912.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study of genetic variation has the potential to aid understanding of the mechanisms underlying the observed inter-individual variation in drug response and by which idiosyncratic adverse effects occur. In this review, we outline current progress in pharmacogenetics using examples to highlight both mechanisms of influence of polymorphisms and research strategies for their detection. In the final sections we discuss contemporary challenges for both researchers and clinicians.
引用
收藏
页码:824 / 831
页数:8
相关论文
共 45 条
[1]   Pharmacogenomics and acquired long QT syndrome [J].
Aerssens, J ;
Paulussen, ADC .
PHARMACOGENOMICS, 2005, 6 (03) :259-270
[2]   Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations [J].
Barber, Mathew J. ;
Mangravite, Lara M. ;
Hyde, Craig L. ;
Chasman, Daniel I. ;
Smith, Joshua D. ;
McCarty, Catherine A. ;
Li, Xiaohui ;
Wilke, Russell A. ;
Rieder, Mark J. ;
Williams, Paul T. ;
Ridker, Paul M. ;
Chatterjee, Aurobindo ;
Rotter, Jerome I. ;
Nickerson, Deborah A. ;
Stephens, Matthew ;
Krauss, Ronald M. .
PLOS ONE, 2010, 5 (03)
[3]   Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy:: a pharmacogenetic analysis of two randomised studies [J].
Bleecker, Eugene R. ;
Postma, Dirkje S. ;
Lawrance, Rachael M. ;
Meyers, Deborah A. ;
Ambrose, Helen J. ;
Goldman, Mitch .
LANCET, 2007, 370 (9605) :2118-2125
[4]  
Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]
[5]   Pharmacogenetics of the human drug-transporter gene MDR1:: impact of polymorphisms on pharmacotherapy [J].
Brinkmann, U ;
Roots, I ;
Eichelbaum, M .
DRUG DISCOVERY TODAY, 2001, 6 (16) :835-839
[6]   Prioritizing GWAS Results: A Review of Statistical Methods and Recommendations for Their Application [J].
Cantor, Rita M. ;
Lange, Kenneth ;
Sinsheimer, Janet S. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2010, 86 (01) :6-22
[7]   Detecting gene-gene interactions that underlie human diseases [J].
Cordell, Heather J. .
NATURE REVIEWS GENETICS, 2009, 10 (06) :392-404
[8]   Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD [J].
Dahl, Ronald ;
Chung, Kian Fan ;
Buhl, Roland ;
Magnussen, Helgo ;
Nonikov, Vladimir ;
Jack, Damon ;
Bleasdale, Patricia ;
Owen, Roger ;
Higgins, Mark ;
Kramer, Benjamin .
THORAX, 2010, 65 (06) :473-479
[9]   HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J].
Daly, Ann K. ;
Donaldson, Peter T. ;
Bhatnagar, Pallav ;
Shen, Yufeng ;
Pe'er, Itsik ;
Floratos, Aris ;
Daly, Mark J. ;
Goldstein, David B. ;
John, Sally ;
Nelson, Matthew R. ;
Graham, Julia ;
Park, B. Kevin ;
Dillon, John F. ;
Bernal, William ;
Cordell, Heather J. ;
Pirmohamed, Munir ;
Aithal, Guruprasad P. ;
Day, Christopher P. .
NATURE GENETICS, 2009, 41 (07) :816-U71
[10]   Copy number variants and common disorders: Filling the gaps and exploring complexity in genome-wide association studies [J].
Estivill, Xavier ;
Armengol, Lluis .
PLOS GENETICS, 2007, 3 (10) :1787-1799